Bavarian Nordic Wins Swiss Approval for Chikungunya Vaccine
COPENHAGEN, Denmark, April 16, 2026 Bavarian Nordic A/S has announced that Swissmedic, the Swiss Agency for Therapeutic Products, has...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
COPENHAGEN, Denmark, April 16, 2026 Bavarian Nordic A/S has announced that Swissmedic, the Swiss Agency for Therapeutic Products, has...
Montpellier, France, November 24, 2025 — Medincell has announced that it has been awarded up to $3 million in...
